Follow up of patients with chronic granulomatous disease diagnosed since 1990

被引:65
作者
Cale, CM
Jones, AM
Goldblatt, D
机构
[1] Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England
[2] Great Ormond St Hosp Sick Children, Dept Immunol, London WC1N 3JH, England
关键词
chronic granulomatous disease; itraconazole; co-trimoxazole;
D O I
10.1046/j.1365-2249.2000.01234.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Outcomes for children with chronic granulomatous disease (CGD) have historically been poor, but significant improvements have occurred with the use of effective antibacterial prophylaxis. The present study aimed to document the clinical course of a cohort of children diagnosed with CGD since 1990 in a single centre. Twenty-one patients were identified, with a median age at last assessment of 4 years and 5 months. A third of these children were diagnosed in infancy because of a positive family history. Of the remaining, there was a median delay between the onset of symptoms and diagnosis of 13 months. No invasive or fungal infections were documented after diagnosis, nor were there any deaths in this cohort. A variety of non-infectious complications were noted, which responded well to steroids. As a group, these children were thriving and weight and height distributions fell within the population norm. All patients were receiving antibacterial prophylaxis, 90% with co-trimoxazole, and all but one patient were receiving a prophylactic anti-fungal agent (itraconazole). Both drugs were well tolerated. In conclusion, this cohort of patients, diagnosed in the last decade, tolerated antibacterial and anti-fungal prophylaxis well and on this regimen have a significantly decreased incidence of infection when compared with historical cohorts. Careful follow up of patients who have had aggressive antibacterial and anti-fungal prophylaxis should continue. The data reported on this cohort of patients should inform the debate about the use of more aggressive treatments, such as bone marrow transplantation, in this disease.
引用
收藏
页码:351 / 355
页数:5
相关论文
共 24 条
  • [1] BERENDES H, 1957, Minn Med, V40, P309
  • [2] Calvino MC, 1996, EUR J PEDIATR, V155, P877
  • [3] Itraconazole resistance in Aspergillus fumigatus
    Denning, DW
    Venkateswarlu, K
    Oakley, KL
    Anderson, MJ
    Manning, NJ
    Stevens, DA
    Warnock, DW
    Kelly, SL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1364 - 1368
  • [4] FILIPOVICH AH, 1992, BLOOD, V80, P270
  • [5] PROGNOSIS OF CHRONIC GRANULOMATOUS-DISEASE
    FINN, A
    HADZIC, N
    MORGAN, G
    STROBEL, S
    LEVINSKY, RJ
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1990, 65 (09) : 942 - 945
  • [6] THE MANAGEMENT OF CHRONIC GRANULOMATOUS-DISEASE
    FISCHER, A
    SEGAL, AW
    SEGER, R
    WEENING, RS
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1993, 152 (11) : 896 - 899
  • [7] Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease
    Foster, CB
    Lehrnbecher, T
    Mol, F
    Steinberg, SM
    Venzon, DJ
    Walsh, TJ
    Noack, D
    Rae, J
    Winkelstein, JA
    Curnutte, JT
    Chanock, SJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) : 2146 - 2155
  • [8] GALLIN JI, 1991, NEW ENGL J MED, V324, P509
  • [9] Chorioretinal lesions in patients and carriers of chronic granulomatous disease
    Goldblatt, D
    Butcher, J
    Thrasher, AJ
    Russell-Eggitt, I
    [J]. JOURNAL OF PEDIATRICS, 1999, 134 (06) : 780 - 783
  • [10] HAUSI M, 1999, PEDIATR INT, V41, P589